AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9098273
Drug: 0.5% timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% timolol applied twice daily
Trial: 375342
Drug: BAY g
RxNorm normalized name: ALCOHOL 70 L in 100 L TOPICAL GEL [Victoria Bay Gel Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY g 5421 (Acarbose) 75 mg
Trial: 375342
Drug: BAY g
RxNorm normalized name: ALCOHOL 70 L in 100 L TOPICAL GEL [Victoria Bay Gel Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY g 5421 (Acarbose) 150 mg
Trial: 375342
Drug: BAY g
RxNorm normalized name: ALCOHOL 70 L in 100 L TOPICAL GEL [Victoria Bay Gel Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY g 5421 (Acarbose) 300 mg
Trial: 375342
Drug: BAY g
RxNorm normalized name: ALCOHOL 70 L in 100 L TOPICAL GEL [Victoria Bay Gel Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY g 5421 (Acarbose)
Trial: 31856945
Drug: 4-session smoking
RxNorm normalized name: TOBACCO SMOKE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-session smoking cessation treatment
Trial: 25607226
Drug: Intravenous caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous caffeine citrate (20 mg/kg) before 2 hours of age
Trial: 14702024
Drug: Independent evaluators'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Independent evaluators' guesses about treatment condition during post-treatment assessments
Trial: 8050210
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) erythropoietin (EPO) at a dose of 120 iu/kg/week
Trial: 8050210
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) erythropoietin (EPO) at a dose of 120 iu/kg/week
Trial: 8050210
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) EPO
Trial: 8050210
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) EPO
Trial: 8050210
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) EPO and Intravenous (IV) EPO
Trial: 3391624
Drug: Oxytetracycline and
RxNorm normalized name: Oxytetracycline and Nystatin Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytetracycline and pyridostigmine in combination
Trial: 28215611
Drug: Prolotherapy injection
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolotherapy injection (n=60)
Trial: 25579292
Drug: 100 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 µg phenylephrine
Trial: 25579292
Drug: 125 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 µg phenylephrine
Trial: 25579292
Drug: 150 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 µg phenylephrine
Trial: 25579292
Drug: Additional doses
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional doses of phenylephrine
Trial: 11099086
Drug: Ciprofloxacin suspension
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin suspension (10 mg/kg twice a day + im placebo; n = 95)
Trial: 11099086
Drug: Intramuscular ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ceftriaxone (50 mg/kg/day + placebo suspension; n = 106)
Trial: 8345978
Drug: Intramuscular ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ceftriaxone
Trial: 9124977
Drug: Hydrochlorothiazide 50
RxNorm normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 50 mg and Amiloride 5 mg orally added to furosemide treatment
Trial: 9124977
Drug: Furosemide (large
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (large doses > or = 80 mg/24 h)
Trial: 30144986
Drug: Triple antibiotic
RxNorm normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triple antibiotic solution (1 mg/mL)
Trial: 1351405
Drug: Continuous medication
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous medication with neuroleptic drugs
Trial: 1351405
Drug: Intermittent medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent medication with crisis intervention
Trial: 1351405
Drug: Intermittent medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent medication with early intervention
Trial: 1351405
Drug: Oral neuroleptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral neuroleptics
Trial: 31298607
Drug: Topical Chloramphenicol
RxNorm normalized name: chloramphenicol Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Chloramphenicol 0.5%-Betamethasone 0.2% (CB)
Trial: 31298607
Drug: Topical Chloramphenicol
RxNorm normalized name: chloramphenicol Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Chloramphenicol 0.5%-Betamethasone 0.2% (CB) associated with Sodium Hyaluronate/Trehalose/Carbomer Gel (HTC-gel)
Trial: 30421481
Drug: Evolocumab on
RxNorm normalized name: Evolocumab only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab on top of atorvastatin 40 mg
Trial: 22449170
Drug: Massage treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage treatment applied by a physical therapist on the posterior deltoid, infraspinatus, and teres minor for 18 minutes, two times a week for 4 weeks.
Trial: 8820892
Drug: Massage treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage treatment
Trial: 17913231
Drug: Oestrogenic drugs
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestrogenic drugs
Trial: 12513901
Drug: Self-administered therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered therapy
Trial: 11422149
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS; 200 microg/day)
Trial: 9495605
Drug: Sertraline treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline treatment (11 weeks) in fibromyalgia patients
Trial: 8285383
Drug: Stepwise lowering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepwise lowering of hemoglobin concentration through venesections (average decrease from 151 +/- 4 to 121 +/- 3 g/L)
Trial: 3190968
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine infusion at 20 mg h‐1
Trial: 3190968
Drug: 0.08% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.08% bupivacaine infusion at 20 mg h‐1
Trial: 28689647
Drug: Pilates method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilates method physical activity programme (2 weekly sessions for 8 weeks)
Trial: 25261268
Drug: Home-based telemonitored
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based telemonitored Nordic walking (NW) training (n=77), five times weekly for eight weeks
Trial: 18165600
Drug: Gabapentin 400
RxNorm normalized name: gabapentin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 400 mg preoperatively, administered every 6 hours up to a total of 1200 mg
Trial: 15253736
Drug: Gentamicin and
RxNorm normalized name: Gentamicin and prednisolone only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin and heparin (5 mg/mL)
Trial: 15253736
Drug: Standard heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard heparin (5000 IU/mL) alone
Trial: 11739835
Drug: Cannabinoid receptor
RxNorm normalized name: Cannabinoid receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabinoid receptor agonist nabilone
Trial: 9415539
Drug: Modified total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified total lymphoid irradiation plus low dose prednisone (TLI-LDP)
Trial: 9415539
Drug: Sham TLI
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham TLI plus identical prednisone therapy (sham TLI-LDP)
Trial: 31662387
Drug: Probiotic treatment
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic treatment (Enterococcus faecalis)
Trial: 31662387
Drug: Concealed placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concealed placebo treatment
Trial: 27243570
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (OT), 24 International Units
Trial: 25981191
Drug: SB010 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB010 (10 mg, inhalation once daily for 28 days)
Trial: 25981191
Drug: Placebo (inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (inhalation once daily for 28 days)
Trial: 24038301
Drug: Combined pharmacotherapy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined pharmacotherapy and psychotherapy
Trial: 16874872
Drug: S. boulardii
RxNorm normalized name: Lactobac. plantarum/S. boulardii/Pediococcus acidilactici 8 billion cell ORAL CAPSULE,DELAYED RELEASE (ENTERIC COATED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S. boulardii (250 mg bid)
Trial: 12972483
Drug: Additional training
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional training on patients in hospital joint injection clinics
Trial: 10633535
Drug: DHEA (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (200 to 500 mg/day)
Trial: 8733067
Drug: Converting-enzyme inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Converting-enzyme inhibitors
Trial: 22698292
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen (HBO) administered at 2 atm twice a day for 40 treatments as an adjunct to surgery and antibiotics
Trial: 22698292
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy alone (surgery and antibiotics)
Trial: 20926017
Drug: Gentacoll implants
RxNorm normalized name: Gentacalm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentacoll implants (10 × 10 × 0.5 cm, 280 mg collagen sponge plus 200 mg gentamicin sulphate)
Trial: 18926150
Drug: 80 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/d of atorvastatin (high-dose regimen)
Trial: 18926150
Drug: 10 mg/d
RxNorm normalized name: Arixtra 10 mg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/d of atorvastatin (low-dose regimen)
Trial: 15894964
Drug: Aspirin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (300 mg/d for 3 weeks)
Trial: 9713273
Drug: Bolus 5‐FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus 5‐FU injection (2-4 min)
Trial: 9713273
Drug: Short-term 5‐FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-term 5‐FU infusion (10-20 min)
Trial: 7994982
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg ticlopidine
Trial: 7994982
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg ticlopidine and 60-150 mg acetylsalicylic acid
Trial: 7994982
Drug: Antiplatelet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet therapy (all groups combined)
Trial: 11550964
Drug: Sulfasalazine 2
RxNorm normalized name: SULFASALAZINE 250MG/5ML SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfasalazine 2 g/day
Trial: 2903927
Drug: Placebo or
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or Sulfasalazine 0.5 g/day
Trial: 2903927
Drug: Sulfasalazine 1
RxNorm normalized name: sulfasalazine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfasalazine 1 g/day or 2 g/day
Trial: 31722313
Drug: Perampanel, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel, a selective non‐competitive AMPA receptor antagonist, administered for 48 weeks
Trial: 16226397
Drug: Concurrent radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent radiotherapy with CMF chemotherapy
Trial: 16226397
Drug: Sequential radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential radiotherapy with CMF chemotherapy
Trial: 12876090
Drug: β-carotene (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-carotene (20 mg)
Trial: 12876090
Drug: α-tocopherol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-tocopherol (50 mg)
Trial: 9594145
Drug: Perindopril 2
RxNorm normalized name: perindopril 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 2 mg a day
Trial: 26544854
Drug: Sham radial
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham radial extracorporeal shock wave therapy (sham rESWT)
Trial: 22595151
Drug: Dispersible formulation
RxNorm normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dispersible formulation of risperidone (2 mg)
Trial: 22595151
Drug: Branded formulation
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded formulation of risperidone (2 mg)
Trial: 16142041
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment (alone or in combination with oral antidiabetic drugs)
Trial: 12084083
Drug: Tacrolimus (FK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus (FK 506) applied 1 x daily for 5 days after the 4-day irritation period
Trial: 10027655
Drug: 50 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg inhaled salmeterol
Trial: 10027655
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg oral bambuterol
Trial: 28103698
Drug: Histamine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine (5 mg)
Trial: 25027109
Drug: Oral recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral recombinant salmon calcitonin tablets (once daily for 1 year)
Trial: 25027109
Drug: Placebo (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (once daily for 1 year)
Trial: 25027109
Drug: Oral recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral recombinant salmon calcitonin tablets (dosing at bedtime or with dinner)
Trial: 25027109
Drug: Oral recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral recombinant salmon calcitonin tablets
Trial: 19411087
Drug: rosuvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin (10 mg/d) for 20 weeks
Trial: 19411087
Drug: rosuvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin (10 mg/d) for 20 weeks + exercise training (3 d/wk from week 10 to week 20)
Trial: 11430440
Drug: LIMIRT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIMIRT treatment (840 nm; 3.0 J cm(‐2), pulse frequency 1 kHz)
Trial: 8053582
Drug: Flumazenil (1
RxNorm normalized name: Flumazenil (18-F)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (1 mg) with high-dose midazolam (group 4)
Trial: 8053582
Drug: Flumazenil (1
RxNorm normalized name: Flumazenil (18-F)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (1 mg) with low-dose midazolam (group 2)
Trial: 1778138
Drug: Flumazenil (1
RxNorm normalized name: Flumazenil (18-F)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (1 mg)
Trial: 28161119
Drug: Ibandronate 150
RxNorm normalized name: ibandronate 150 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate 150 mg every 4 weeks
Trial: 19112213
Drug: Short daily
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short daily hemodialysis (6 times per week for 1.5 to 2.75 hours)
Trial: 24875804
Drug: Short daily
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short daily hemodialysis
Trial: 9793661
Drug: Subcutaneous and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous and peritoneal bupivacaine (1.5 mg.kg‐1 bupivacaine 0.5%)
Trial: 9793661
Drug: Subcutaneous bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous bupivacaine (1.5 mg.kg‐1 bupivacaine 0.5%)
Trial: 7697953
Drug: Buspirone (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (5, 10, and 20 mg)
Trial: 7697953
Drug: Buspirone (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (doses lower than 20 mg)
Trial: 7697953
Drug: Sumatriptan (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan (50, 100, and 200 mg)
Trial: 7697953
Drug: Sumatriptan (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan (doses unspecified)
Trial: 2515136
Drug: bepridil (100-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bepridil (100-400 mg/d)
Trial: 2515136
Drug: propranolol (60-240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propranolol (60-240 mg/d)
Trial: 852404
Drug: BM 15.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BM 15.075 at 450 mg
Trial: 852404
Drug: BM 15.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BM 15.075 at 600 mg
Trial: 24950758
Drug: 2-micron continuous-wave
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-micron continuous-wave laser treatment
Trial: 23852296
Drug: 25 mg/day
RxNorm normalized name: estradiol 0.025 MG/Day Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/day mifepristone for 3 months
Trial: 23852296
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day mifepristone for 3 months
Trial: 15275754
Drug: 5.8% hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.8% hypertonic saline (0.5 ml in each side for each bilateral injection)
Trial: 10190658
Drug: Ropinirole (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropinirole (three times daily for 6 weeks)
Trial: 10190658
Drug: Digoxin alone
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin alone (once daily)
Trial: 10190658
Drug: Placebo (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (three times daily for 1 week)
Trial: 7762498
Drug: Heparin-induced extracorporeal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) treatments
Trial: 6383614
Drug: No drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug therapy
Trial: 7762498
Drug: HELP treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HELP treatments
Trial: 2082485
Drug: Dipyridamole 100
RxNorm normalized name: dipyridamole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole 100 mg t.i.d. plus warfarin (Study 1)
Trial: 2082485
Drug: Slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow release capsules of dipyridamole plus warfarin (Study 2)
Trial: 2082485
Drug: Tablet form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet form dipyridamole plus warfarin (Study 2)
Trial: 371902
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg metoprolol once daily
Trial: 371902
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg metoprolol once daily
Trial: 371902
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg and 300 mg metoprolol
Trial: 30706788
Drug: Ondansetron (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (4 & 8 mg)
Trial: 24969380
Drug: Galantamine (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine (target dose: 24 mg)
Trial: 24969380
Drug: Risperidone (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (target dose: 1.5 mg)
Trial: 15735116
Drug: Gemcitabine (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1,000 mg/m(2), days 1 and 4), epirubicin (90 mg/m(2), day 1), and paclitaxel (175 mg/m(2), day 1)
Trial: 15735116
Drug: Fluorouracil (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil (500 mg/m(2), day 1), epirubicin (90 mg/m(2), day 1), and cyclophosphamide (500 mg/m(2), day 1)
Trial: 12139821
Drug: 5 mg/24
RxNorm normalized name: Iron 5 MG/240 ML Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/24 h nitroglycerin patch
Trial: 12139821
Drug: 10 mg/24
RxNorm normalized name: donepezil 10 mg/24 hr transdermal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/24 h nitroglycerin patch
Trial: 12139821
Drug: 15 mg/24
RxNorm normalized name: Annovera, 0.013 mg-0.15 mg/24 hours vaginal ring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/24 h nitroglycerin patch